FDA issues complete response letter for Cingulate's ADHD drug CTx-1301

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. JBLU
3. CDNS
4. META
5. ANT
6. PECO
7. SSD
8. AGYS
9. HWKN
10. INTC

Go back to FDA issues complete response letter for Cingulate's ADHD drug CTx-1301

Cingulate Receives Complete Response Letter from FDA for CTx-1301

June 2, 2026 8:00 AM EDT

No Clinical Safety or Efficacy Concerns Currently Identified 
Agency Feedback Primarily Focused on CMC-Related Requests
Company Plans Prompt Response and Submission of Requested Information
Company is Well Capitalized with Nearly $30 Million Cash on Hand

KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for its New Drug Application (NDA) for... More